SynthesisPloS one2013
Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis.
Synthesis in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia (English Version).Journal of the anus, rectum and colon · 2026Review
- Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy.Cancers · 2023Review
- Overcoming cancer risk in inflammatory bowel disease: new insights into preventive strategies and pathogenesis mechanisms including interactions of immune cells, cancer signaling pathways, and gut microbiota.Frontiers in immunology · 2023Review
- Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention.Current oncology (Toronto, Ont.) · 2022Review
- Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review.Dermatology and therapy · 2022Review
- Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management.Gastroenterology · 2022Review
- 5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?Inflammatory intestinal diseases · 2022Review
- Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes.International journal of molecular sciences · 2021Review
- Colorectal Cancer in Inflammatory Bowel Disease.Clinics in colon and rectal surgery · 2018Review
- Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.World journal of gastroenterology · 2016Review
- Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2016Article
- Article
- Chemoprevention of colorectal cancer.Digestive diseases (Basel, Switzerland) · 2015Review
- Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis.World journal of gastroenterology · 2014Article
- The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.Gastrointestinal endoscopy clinics of North America · 2014Review
- Use of thiopurines in inflammatory bowel disease: Safety issues.World journal of gastrointestinal pharmacology and therapeutics · 2014Review
- Age of onset of inflammatory bowel disease is the strongest risk factor for the development of malignancy.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInflammatory bowel disease (IBD) is commonly treated with thiopurines such as azathioprine and mercaptopurine for the maintenance of remission. Studies examining chemopreventive of these medications on colorectal neoplasm in IBD patients have yielded conflicting results. We performed a meta-analysis to assess the role of thiopurines for this indication.
methodsWe performed a systematic search of PubMed, Web of Science, EMBASE and Cochrane to identify studies reporting colorectal neoplasm from IBD patients treated with thiopurines and conducted a meta-analysis of pooled relative risk (RR) using the random effects model.
resultsNine case-control and ten cohort studies fulfilled the inclusion criteria. The use of thiopurines was associated with a statistically significant decreased incidence of colorectal neoplasm (summary RR=0.71, 95% CI=0.54-0.94, p=0.017), even after adjustment for duration and extent of the disease, but there was high heterogeneity among studies (I(2)=68.0%, p<0.001). The RR of advanced neoplasm (high-grade dysplasia and cancer) was 0.72 (95%CI=0.50-1.03, p=0.070) and that of cancer was 0.70 (95% CI=0.46-1.09, p=0.111) for thiopurine-treated patients. Heterogeneity of the studies was affected by the sample size (</≥ 100 cases) and whether the patients had longstanding colitis (≥ 7 years).
conclusionThe current meta-analysis revealed that thiopurines had a chemopreventive effect of colorectal neoplasms and a tendency of reducing advanced colorectal neoplasms in IBD. Due to the heterogeneity of included studies, these results should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.